Federal Register Notice: FDA has determined the regulatory review period for Janssen Pharmaceutica’s Sirturo is 2,213 days for extending a patent that claims the human drug product. Sirturo (bedaquiline) is indicated for combination therapy in adults with pulmonary multi-drug resistant tuberculosis. To view this notice, click here.
